Tag: Sotrovimab

FDA limits use of GlaxoSmithKline and Vir’s COVID-19 antibody treatment in some geographic areas

The United States Food and Drug Administration stated GlaxoSmithKline and Vir Biotech's COVID-19 antibody treatment should not be...

Xevudy (sotrovimab) granted marketing authorisation by the EC for the early treatment of COVID-19

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the European Commission (EC) has granted marketing authorisation to Xevudy (sotrovimab) for...

COVID-19 dual-antibody therapies prevent emergence of drug resistance

Administration of antibody therapies bypasses the body’s slower and sometimes less effective process of making its own antibodies.